PSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Poseida Therapeutics's Revenue for the three months ended in Sep. 2024 was $71.7 Mil. Poseida Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $296.1 Mil. Therefore, Poseida Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.24.
Asset Turnover is linked to ROE % through Du Pont Formula. Poseida Therapeutics's annualized ROE % for the quarter that ended in Sep. 2024 was 109.36%. It is also linked to ROA % through Du Pont Formula. Poseida Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was 27.33%.
The historical data trend for Poseida Therapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Asset Turnover | Get a 7-Day Free Trial | - | - | 0.10 | 0.42 | 0.21 |
Poseida Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Asset Turnover | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.03 | 0.09 | 0.11 | 0.09 | 0.24 |
For the Biotechnology subindustry, Poseida Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Poseida Therapeutics's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Poseida Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 64.703 | / | ( (351.837 | + | 273.885) | / 2 ) |
= | 64.703 | / | 312.861 | |||
= | 0.21 |
Poseida Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Sep. 2024 ) | / | ( (Total Assets (Q: Jun. 2024 ) | + | Total Assets (Q: Sep. 2024 )) | / count ) |
= | 71.748 | / | ( (298.686 | + | 293.577) | / 2 ) |
= | 71.748 | / | 296.1315 | |||
= | 0.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Poseida Therapeutics (NAS:PSTX) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Poseida Therapeutics's annulized ROE % for the quarter that ended in Sep. 2024 is
ROE %** | (Q: Sep. 2024 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 80.94 | / | 74.014 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (80.94 / 286.992) | * | (286.992 / 296.1315) | * | (296.1315/ 74.014) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 28.2 % | * | 0.9691 | * | 4.001 |
= | ROA % | * | Equity Multiplier | ||
= | 27.33 % | * | 4.001 | ||
= | 109.36 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Poseida Therapeutics's annulized ROA % for the quarter that ended in Sep. 2024 is
ROA % | (Q: Sep. 2024 ) | ||
= | Net Income | / | Total Assets |
= | 80.94 | / | 296.1315 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (80.94 / 286.992) | * | (286.992 / 296.1315) |
= | Net Margin % | * | Asset Turnover |
= | 28.2 % | * | 0.9691 |
= | 27.33 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Poseida Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark J Gergen | director, officer: President and CBO | C/O MIRATI THERAPEUTICS INC., 9393 TOWN CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Luke Corning | director | 614 DAVIS STREET, EVANSTON IL 60201 |
Marcea Bland Lloyd | director | 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Rafael Amado | director | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Kristin Yarema | officer: President, Cell Therapy | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Malin Life Sciences Holdings Ltd | 10 percent owner | 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ---- |
Eric Ostertag | director, 10 percent owner, officer: Chief Executive Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Kerry D. Ingalls | officer: Chief Operating Officer | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brent Warner | officer: President, Gene Therapy | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Matthew A. Spear | officer: Chief Medical Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Harry J Leonhardt | officer: GC & Chief Compliance Officer | C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
David Hirsch | director | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
From GuruFocus
By GuruFocus News • 02-07-2025
By GuruFocus News • 11-26-2024
By PRNewswire • 11-11-2024
By PRNewswire • 12-09-2024
By GuruFocus News • 11-26-2024
By PRNewswire • 08-05-2024
By PRNewswire • 11-27-2024
By PRNewswire • 08-29-2024
By PRNewswire • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.